The U.S. Food and Drug Administration has issued a labeling approval (status "AP") for the generic drug application ANDA078251 submitted by Glenmark Pharmaceuticals Inc., USA.
The approved product is carvedilol, an oral tablet classified as a prescription drug. Four tablet strengths are listed: 3.125 mg (product number 001), 6.25 mg (002), 12.5 mg (003) and 25 mg (004). The associated NDC codes span 68462‑162‑01 to 68462‑165‑10.
Labeling submissions for this ANDA have been approved on multiple dates, most recently on 2023‑11‑01 (submission number 19). Earlier approvals were recorded on 2007‑07‑13, 2014‑09‑26 and 2013‑05‑07.
Cập nhật pháp chế25 thg 9, 2026•1 phút đọc
FDA Approves Glenmark’s Carvedilol Generic Tablets (ANDA078251)
The FDA has granted labeling approval for Glenmark Pharmaceuticals’ generic carvedilol tablets (ANDA078251), available in 3.125 mg, 6.25 mg, 12.5 mg and 25 mg oral dosage forms.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá